Skip to main content
. Author manuscript; available in PMC: 2014 Jan 13.
Published in final edited form as: Int J Oncol. 2011 Jun 16;39(4):891–898. doi: 10.3892/ijo.2011.1085

Figure 4.

Figure 4

Effects of siRNA knockdown of Wnt-1 on cancer stem cells derived from TNBC cells. Cancer stem cells from CRL2335 were transfected with Wnt-1 siRNA or random siRNA or treated with cisplatin plus TRAIL. Cancer stem cell extracts were prepared and analyzed for Wnt-1, phospho-β-catenin and cyclin D1 by Western blotting (A). Equal protein loading was compared with that of actin. (B) Under similar conditions mammosphere formation ability was assessed using protocols described in methods. Data shows a combination of cisplatin plus TRAIL treatment significantly inhibits Wnt-1 signaling and reduced mammosphere formation ability of CSCs.